Targeting a specific protein to fight acute myeloid leukemia
Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia
This study is looking at a new way to help people with acute myeloid leukemia (AML) by using a special treatment that targets a protein called PRMT9 to boost the immune system's fight against the leukemia cells, which could lead to better outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10997405 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for patients with acute myeloid leukemia (AML) by targeting protein arginine methyltransferases (PRMTs), particularly PRMT9. The approach involves inhibiting PRMT9 to activate the immune response against AML cells, which have been difficult to treat with existing therapies. By using a combination of a novel PRMT9 inhibitor and immune checkpoint inhibitors, the research aims to enhance the body's ability to eliminate leukemia cells. Patients may benefit from this innovative treatment strategy that seeks to overcome the limitations of current AML therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have not responded well to existing treatments.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in targeting immune pathways in leukemia, suggesting that this approach may be effective, although the specific targeting of PRMT9 is relatively novel.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Li, Ling — Beckman Research Institute/city of Hope
- Study coordinator: Li, Ling
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.